Recap: Esperion Therapeutics Q3 Earnings

Shares of Esperion Therapeutics ESPR fell 2% in after-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share fell 21.83% over the past year to ($3.07), which beat the estimate of ($3.41).

Revenue of $3,833,000 rose by 290.72% year over year, which missed the estimate of $5,930,000.

Guidance

Esperion Sees FY 2020 R&D Expenses Between $135M And $145M, SG&A Expenses Between $200M And $210M

Conference Call Details

Date: Nov 02, 2020

Time: 04:30 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/d2vhtoax

Recent Stock Performance

52-week high: $76.98

52-week low: $24.82

Price action over last quarter: down 14.87%

Company Profile

Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. The firm has Business of researching, developing and commercializing therapies for the treatment of patients with the elevated LDL-C operating segment.